Search

Author/Creator Amadori, S.

1. S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML. (23rd June 2022)

Authors:
Erba, H.; Montesinos, P.; Vrhovac, R.; Patkowska, E.; Kim, H.-J.; Zak, P.; Wang, P.-N.; Mitov, T.; Hanyok, J.; Liu, L.; Benzohra, A.; Lesegretain, A.; Cortes, J.; Perl, A.; Sekeres, M.; Dombret, H.; Amadori, S.; Wang, J.; Levis, M.; Schlenk, R.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022)

Authors:
Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; Audisio, E.; Candoni, A.; Legrand, O.; Foà, R.; Gaidano, G.; van Lammeren-Venema, D.; Posthuma, E. F.; Hoogendoorn, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search